Optimizing Fecal Occult Blood Test (FOBT) Colorectal Cancer Screening Using Gut Bacteriome as a Biomarker.

16S rRNA gene sequencing Lesion grade iFOBT screening

Journal

Clinical colorectal cancer
ISSN: 1938-0674
Titre abrégé: Clin Colorectal Cancer
Pays: United States
ID NLM: 101120693

Informations de publication

Date de publication:
13 Oct 2023
Historique:
received: 21 06 2023
revised: 03 10 2023
accepted: 05 10 2023
medline: 19 11 2023
pubmed: 19 11 2023
entrez: 18 11 2023
Statut: aheadofprint

Résumé

Colorectal cancer (CRC) is a major cause of cancer mortality in the world. One of the most widely used screening tests for CRC is the immunochemical fecal occult blood test (iFOBT), which detects human hemoglobin from patient's stool sample. Although it is highly efficient in detecting blood from patients with gastro-intestinal lesions, such as polyps and cancers, the iFOBT has a high rate of false positive discovery. Recent studies suggested gut bacteria as a promising noninvasive biomarker for improving the diagnosis of CRC. In this study, we examined the composition of gut bacteria using iFOBT leftover from patients undergoing screening test along with a colonoscopy. After collecting data from more than 800 patients, we considered 4 groups for this study. The first and second groups were respectively "healthy" in which the patients had either no blood in their stool or had blood but no lesions. The third and fourth groups of patients had both blood in their stools with precancerous and cancerous lesions and considered either as low-grade and high-grade lesion groups, respectively. An amplification of 16S rRNA (V4 region) gene was performed, followed by sequencing along with various statistical and bioinformatic analysis. We analyzed the composition of the gut bacteriome at phylum, class, genus, and species levels. Although members of the Firmicute phylum increased in the 3 groups compared to healthy patients, the phylum Actinobacteriota was found to decrease. Moreover, Blautia obeum and Anaerostipes hadrus from the phylum Firmicutes were increased and Collinsella aerofaciens from phylum Actinobacteriota was found decreased when healthy group is compared to the patients with high-grade lesions. Finally, among the 5 machine learning algorithms used to perform our analysis, both elastic net (AUC > 0.7) and random forest (AUC > 0.8) performs well in differentiating healthy patients from 3 other patient groups having blood in their stool. Our study integrates the iFOBT screening tool with gut bacterial composition to improve the prediction of CRC lesions.

Sections du résumé

BACKGROUND BACKGROUND
Colorectal cancer (CRC) is a major cause of cancer mortality in the world. One of the most widely used screening tests for CRC is the immunochemical fecal occult blood test (iFOBT), which detects human hemoglobin from patient's stool sample. Although it is highly efficient in detecting blood from patients with gastro-intestinal lesions, such as polyps and cancers, the iFOBT has a high rate of false positive discovery. Recent studies suggested gut bacteria as a promising noninvasive biomarker for improving the diagnosis of CRC. In this study, we examined the composition of gut bacteria using iFOBT leftover from patients undergoing screening test along with a colonoscopy.
METHODS METHODS
After collecting data from more than 800 patients, we considered 4 groups for this study. The first and second groups were respectively "healthy" in which the patients had either no blood in their stool or had blood but no lesions. The third and fourth groups of patients had both blood in their stools with precancerous and cancerous lesions and considered either as low-grade and high-grade lesion groups, respectively. An amplification of 16S rRNA (V4 region) gene was performed, followed by sequencing along with various statistical and bioinformatic analysis.
RESULTS RESULTS
We analyzed the composition of the gut bacteriome at phylum, class, genus, and species levels. Although members of the Firmicute phylum increased in the 3 groups compared to healthy patients, the phylum Actinobacteriota was found to decrease. Moreover, Blautia obeum and Anaerostipes hadrus from the phylum Firmicutes were increased and Collinsella aerofaciens from phylum Actinobacteriota was found decreased when healthy group is compared to the patients with high-grade lesions. Finally, among the 5 machine learning algorithms used to perform our analysis, both elastic net (AUC > 0.7) and random forest (AUC > 0.8) performs well in differentiating healthy patients from 3 other patient groups having blood in their stool.
CONCLUSION CONCLUSIONS
Our study integrates the iFOBT screening tool with gut bacterial composition to improve the prediction of CRC lesions.

Identifiants

pubmed: 37980216
pii: S1533-0028(23)00091-9
doi: 10.1016/j.clcc.2023.10.004
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Disclosure The authors have stated that they have no conflicts of interest.

Auteurs

Moumita Roy Chowdhury (MR)

Department of Biochemistry and Functional Genomics, University of Sherbrooke, Sherbrooke, Canada.

Karina Gisèle Mac Si Hone (KGMS)

Department of Biochemistry and Functional Genomics, University of Sherbrooke, Sherbrooke, Canada; Department of Biology, University of Sherbrooke, Sherbrooke, Canada.

Karine Prévost (K)

Department of Biochemistry and Functional Genomics, University of Sherbrooke, Sherbrooke, Canada.

Philippe Balthazar (P)

Department of Biochemistry and Functional Genomics, University of Sherbrooke, Sherbrooke, Canada.

Mariano Avino (M)

Department of Biochemistry and Functional Genomics, University of Sherbrooke, Sherbrooke, Canada.

Mélina Arguin (M)

Department of Biochemistry and Functional Genomics, University of Sherbrooke, Sherbrooke, Canada.

Jude Beaudoin (J)

Department of Biochemistry and Functional Genomics, University of Sherbrooke, Sherbrooke, Canada.

Mandy Malick (M)

Department of Biochemistry and Functional Genomics, University of Sherbrooke, Sherbrooke, Canada.

Michael Desgagné (M)

Department of Biochemistry and Functional Genomics, University of Sherbrooke, Sherbrooke, Canada.

Gabriel Robert (G)

Department of Biochemistry and Functional Genomics, University of Sherbrooke, Sherbrooke, Canada.

Michelle Scott (M)

Department of Biochemistry and Functional Genomics, University of Sherbrooke, Sherbrooke, Canada.

Jean Dubé (J)

Department of Biochemistry and Functional Genomics, University of Sherbrooke, Sherbrooke, Canada.

Isabelle Laforest-Lapointe (I)

Department of Biology, University of Sherbrooke, Sherbrooke, Canada. Electronic address: isabelle.laforest-lapointe@usherbrooke.ca.

Eric Massé (E)

Department of Biochemistry and Functional Genomics, University of Sherbrooke, Sherbrooke, Canada. Electronic address: eric.masse@usherbrooke.ca.

Classifications MeSH